[go: up one dir, main page]

DK0831791T3 - Transport af lægemiddelstoffer til den nedre gastrointestinalkanal - Google Patents

Transport af lægemiddelstoffer til den nedre gastrointestinalkanal

Info

Publication number
DK0831791T3
DK0831791T3 DK96919237T DK96919237T DK0831791T3 DK 0831791 T3 DK0831791 T3 DK 0831791T3 DK 96919237 T DK96919237 T DK 96919237T DK 96919237 T DK96919237 T DK 96919237T DK 0831791 T3 DK0831791 T3 DK 0831791T3
Authority
DK
Denmark
Prior art keywords
weight
drug
composition
transport
gastrointestinal tract
Prior art date
Application number
DK96919237T
Other languages
English (en)
Inventor
David R Friend
David Wong
Original Assignee
Watson Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,974 external-priority patent/US5656294A/en
Application filed by Watson Lab Inc filed Critical Watson Lab Inc
Application granted granted Critical
Publication of DK0831791T3 publication Critical patent/DK0831791T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK96919237T 1995-06-07 1996-06-07 Transport af lægemiddelstoffer til den nedre gastrointestinalkanal DK0831791T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/486,974 US5656294A (en) 1995-06-07 1995-06-07 Colonic delivery of drugs
US08/602,611 US5811388A (en) 1995-06-07 1996-02-16 Delivery of drugs to the lower GI tract
PCT/US1996/009609 WO1996040078A1 (en) 1995-06-07 1996-06-07 Delivery of drugs to the lower gi tract

Publications (1)

Publication Number Publication Date
DK0831791T3 true DK0831791T3 (da) 2005-01-31

Family

ID=27048854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919237T DK0831791T3 (da) 1995-06-07 1996-06-07 Transport af lægemiddelstoffer til den nedre gastrointestinalkanal

Country Status (11)

Country Link
US (1) US5811388A (da)
EP (1) EP0831791B1 (da)
JP (1) JPH11507357A (da)
AT (1) ATE280572T1 (da)
AU (1) AU6163096A (da)
CA (1) CA2224170A1 (da)
DE (1) DE69633721T2 (da)
DK (1) DK0831791T3 (da)
ES (1) ES2231815T3 (da)
PT (1) PT831791E (da)
WO (1) WO1996040078A1 (da)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US6162464A (en) * 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
WO1999016454A1 (en) * 1997-09-26 1999-04-08 Medeva Europe Limited Pharmaceutical composition for the treatment of inflammatory bowel disease
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6251863B1 (en) 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
DK1183014T3 (da) * 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
EP1368000A4 (en) * 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
DK1424997T3 (da) * 2001-09-14 2008-01-07 Scolr Inc Aminosyremoduleret dosisform til forlænget frigivelse
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US6949256B2 (en) * 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
US7887838B2 (en) 2002-01-18 2011-02-15 Banner Pharmacaps, Inc. Non-gelatin film and method and apparatus for producing same
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
JP2006501310A (ja) * 2002-08-29 2006-01-12 アクティブバイオティクス インコーポレイティッド クロストリジウム・ディフィシレの感染およびそれに関係する疾患を治療するための方法および試薬
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
WO2004052374A1 (en) * 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US20040142968A1 (en) * 2003-01-17 2004-07-22 Donald Price Method and kit for treating lower bowel pain
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
US20050008677A1 (en) * 2003-04-14 2005-01-13 Fmc Corporation Delivery system of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
US7816341B2 (en) * 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
US20050019295A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
JP2007528357A (ja) * 2003-04-14 2007-10-11 エフ　エム　シー　コーポレーション ゲルフィルムを製造するための方法
US20050013847A1 (en) * 2003-04-14 2005-01-20 Fmc Corporation Delivery systems of homogeneous, thermoreversible alginate films
US20050048185A1 (en) * 2003-04-14 2005-03-03 Fmc Corporation Delivery systems of homogeneous, thermoreversible low viscosity polymannan gum films
US20050019294A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible alginate films and soft capsules made therefrom
KR101192722B1 (ko) 2003-04-24 2012-10-18 자고텍 아게 정해진 핵 위치를 가지는 서방성 정제
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
ES2350396T3 (es) * 2003-09-15 2011-01-21 Nycomed Gmbh Uso de ciclesonida para el tratamiento de enfermedades intestinales inflamatorias.
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
EP1740188A1 (en) * 2004-04-20 2007-01-10 Altana Pharma AG Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
AU2005281797B2 (en) * 2004-09-10 2011-07-07 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
AU2011232809B2 (en) * 2004-09-10 2014-03-20 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
MX2009001248A (es) 2006-08-03 2009-02-11 Nitec Pharma Ag Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2012012147A2 (en) 2010-06-30 2012-01-26 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
KR101890959B1 (ko) 2010-11-04 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
UA121270C2 (uk) 2015-11-24 2020-04-27 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Проліки jak-інгібуючої сполуки для лікування запального захворювання шлунково-кишкового тракту
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN110418796A (zh) 2017-03-08 2019-11-05 施万生物制药研发Ip有限责任公司 托法替尼(tofacitinib)的葡萄糖苷酸前药
US10233174B2 (en) 2017-05-23 2019-03-19 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
JP2020520955A (ja) 2017-05-23 2020-07-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ヤヌスキナーゼ阻害剤のグルクロニドプロドラッグ
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
AU2017445093B2 (en) * 2017-12-29 2024-09-19 Exentis Knowledge Gmbh Drug delivery system
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069360B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022254456A1 (en) * 2021-06-01 2022-12-08 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4894233A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for decongestants
WO1986006627A1 (en) * 1985-05-15 1986-11-20 Riker Laboratories, Inc. Sustained release theophylline compositions and processes
SE8601563D0 (sv) * 1986-04-08 1986-04-08 Carbomatrix Ab Matrismaterial, forfarande for framstellning derav och anvendning derav
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5466469A (en) * 1988-06-28 1995-11-14 Cibus Pharmaceutical, Inc. Granular drug delivery system
CA1334379C (en) * 1987-11-24 1995-02-14 James William Mcginity Method for preparing a solid sustained release form of a functionally active composition
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US5445826A (en) * 1988-06-28 1995-08-29 Cibus Pharmaceutical, Inc. Delivery system containing a gel-forming dietary fiber and a drug
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
JP2683391B2 (ja) * 1988-11-30 1997-11-26 日清製粉株式会社 小麦ふすまからのヘミセルロースを基材とする徐放性組成物
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
WO1991016881A1 (en) * 1990-05-04 1991-11-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Colonic drug delivery system
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
FR2667242B1 (fr) * 1990-09-28 1994-11-25 Rhone Poulenc Sante Nouvelles formes orales a liberation prolongee avec un temps de latence au niveau stomacal amoindri.
EP0481240B1 (de) * 1990-10-18 1996-12-11 Basf Aktiengesellschaft Galactomannanderivate zur Umhüllung oder Einbettung von Arzneimittelwirkstoffen
DE9015551U1 (de) * 1990-11-14 1992-03-12 Röhm GmbH, 6100 Darmstadt Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
EP0676967A4 (en) * 1992-12-30 1996-10-02 Fmc Corp RELEASED, EXTENDED, EASY TO PRODUCE EXCIPIENT, BASED ON KONJAC GLUCOMANNANE.
JPH10509981A (ja) * 1994-12-01 1998-09-29 サイバス ファーマシューティカル，インコーポレイティド 高等植物から得られうる粉末状親水コロイドゴムを用いる持効性薬剤送出
FI972305A7 (fi) * 1994-12-01 1997-05-30 Cibus Pharmaceutical Inc NSAID:n anto käyttämällä ylemmistä kasveista saatavissa olevaa jauhett ua hydrokolloidikumia
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs

Also Published As

Publication number Publication date
PT831791E (pt) 2005-02-28
ES2231815T3 (es) 2005-05-16
JPH11507357A (ja) 1999-06-29
WO1996040078A1 (en) 1996-12-19
EP0831791A4 (en) 1998-08-26
CA2224170A1 (en) 1996-12-19
DE69633721T2 (de) 2005-12-22
EP0831791B1 (en) 2004-10-27
EP0831791A1 (en) 1998-04-01
DE69633721D1 (de) 2004-12-02
US5811388A (en) 1998-09-22
ATE280572T1 (de) 2004-11-15
AU6163096A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
DK0831791T3 (da) Transport af lægemiddelstoffer til den nedre gastrointestinalkanal
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
DZ1884A1 (fr) Formulations orales liquides d'alendronate.
NO895167D0 (no) Fremgangsmaate for behandling av tannrotsykdom ved vedvarende avgivelse av et farmasoeytisk middel til crevikularlommen, stoffblanding for dette og apparat for administrering derav.
JP2005515966A5 (da)
ATE164080T1 (de) Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
DE69920689D1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
DE69532678D1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel
RU2007104095A (ru) Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств
DK0490944T3 (da) Transmucosal doseringsform
NO940376D0 (no) Doseringsanordning for avgivelse av medikament over et tidsrom med kort varighet
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
KR19980701720A (ko) 세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
CA1306950C (en) Buccal administration of estrogens
Scharman et al. Efficiency of whole bowel irrigation with and without metoclopramide pretreatment
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
MX9704079A (es) Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores.
NO972486L (no) Vedvarende frigjöring av legemiddel ved anvendelse av en pulverisert hydrokolloid-gummi som kan oppnås fra höyere planter
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
JPH01279818A (ja) 白髪黒化剤